<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363082">
  <stage>Registered</stage>
  <submitdate>26/09/2012</submitdate>
  <approvaldate>28/09/2012</approvaldate>
  <actrnumber>ACTRN12612001040853</actrnumber>
  <trial_identification>
    <studytitle>Does pulsatile administration of glucagon-like peptide-1 (GLP-1) when compared to continuous infusion have a greater effect on insulin secretion and blood glucose lowering in healthy humans?</studytitle>
    <scientifictitle>The effects of pulsatile, when compared to continuous, infusion of glucagon-like peptide-1 on insulin secretion and blood glucose in healthy humans</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Blood Glucose</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intervention: 1ml bolus of glucagon-like peptide-1 (GLP-1)at 3.6 pmol/kg every 6 minutes and a continuous infusion of 0.9% isotonic saline (1 ml/min) both intravenously for 120min.

Subjects will be studied on three occasions sperated by a minimum of 3 days.</interventions>
    <comparator>Control: continuous infusion of GLP-1 at 0.6 pmol/kg/min (1 ml/min) and a 1ml bolus of 0.9% isotonic saline every 6 minutes both intravenously for 120min.

Placebo: continuous infusion of 0.9% isotonic saline  (1 ml/min) and a 1ml bolus of 0.9% isotonic saline every 6 minutes both intravenously for 120min.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine whether pulsatile administration of GLP-1 causes greater perturbations of insulin secretion when compared with continuous administration.</outcome>
      <timepoint>Insulin levels will be measured every minute for 120min</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine whether pulsatile administration of GLP-1 has a more potent glucose-lowering effect when compared with continuous administration.</outcome>
      <timepoint>Glucose will be measured every minute for 120min</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy volunteers able to give informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>35</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Inability to give informed consent
History of diabetes
Women who are pregnant or lactating
History of pancreatitis
Haemoglobin &lt;125g/L for women and &lt;135g/L for men
Glycated haemoglobin (HbA1c) &gt;6.0 %
Ferritin levels for women &lt;10microgram/L and &lt;20microgram/L for men
Estimated glomerular filtration rate &lt; 60ml/min
Impaired liver function (ALT: &gt;55 U/L; Albumin: &lt;34g/l; ALP: &gt;110 U/L; Bilirubin: &gt;25 micro mol; GGT: &gt;80U/L)
Blood donation within the previous 12 weeks
BMI &lt;18.5 or &gt;30kgm^2
Taking blood-glucose lowering drugs</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Subjects will be recruited from our existing database of volunteers

The study is a randomised, double blind, double dummy, cross-over study. The randomisation will be performed by the Department of Pharmacy, Royal Adelaide Hospital and the randomisation schedule will be kept in a locked facility within the Department of Pharmacy and the investigators will have no access to the schedule during the study period. Once the peptide is reconstituted the study drug or placebo is packaged and labelled study drug. The investigator will receive the study drug from the pharmacy department and have no involvement in preparation of solution or randomisation schedule.</concealment>
    <sequence>Randomisation will be computer generated</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/01/2013</anticipatedstartdate>
    <actualstartdate>5/04/2013</actualstartdate>
    <anticipatedenddate>1/07/2013</anticipatedenddate>
    <actualenddate>16/08/2013</actualenddate>
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>The Royal Adelaide Hospital - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Adelaide Hospital Intensive Care Unit</primarysponsorname>
    <primarysponsoraddress>Intensive Care Unit
Level 4 Royal Adelaide Hospital
North Terrace
Adelaide
5000 SA</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council (NHMRC)</fundingname>
      <fundingaddress>Level 5, 20 Allara Street
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Adam Deane</sponsorname>
      <sponsoraddress>Intensive Care Unit
Level 4 Royal Adelaide Hospital
North Terrace
Adelaide
5000 SA</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the optimum administration method of glucagon-like peptide-1 (GLP-1), by evaluating whether pulsatile administration of GLP-1 causes greater insulin secretion and glucose lowering when compared with continuous administration.</summary>
    <trialwebsite />
    <publication>The publication is currently in the process of being completed for submission to an international medical journal.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Research Ethics Committe</ethicname>
      <ethicaddress>Level 3
Hanson Institute
Royal Adelaide Hospital
North Terrace 
Adelaide
SA 5000</ethicaddress>
      <ethicapprovaldate>26/09/2012</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>24/04/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Adam Deane</name>
      <address>Intensive Care Unit
Royal Adelaide Hospital
North Terrace 
Adelaide
SA 5000</address>
      <phone>+61 8 8222 4000</phone>
      <fax />
      <email>adam.deane@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Adam Deane</name>
      <address>Intensive Care Unit
Royal Adelaide Hospital
North Terrace 
Adelaide
SA 5000</address>
      <phone>+61 8 8222 4000</phone>
      <fax />
      <email>adam.deane@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Adam Deane </name>
      <address>ICU Research
Royal Adelaide Hospital
North Terrace
Adelaide
SA 5000</address>
      <phone>+61 8 8222 4000</phone>
      <fax />
      <email>adam.deane@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>